Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

被引：0

作者：

Nazzareno Galiè

Sean Gaine

Richard Channick

J. Gerry Coghlan

Marius M. Hoeper

Irene M. Lang

Vallerie V. McLaughlin

Cheryl Lassen

Lewis J. Rubin

Shu-Fang Hsu Schmitz

Olivier Sitbon

Victor F. Tapson

Kelly M. Chin

机构：

[1] University of Bologna and IRCCS-S.Orsola University Hospital,Alma Mater Studiorum

[2] Mater Misericordiae University Hospital,David Geffen School of Medicine

[3] UCLA,undefined

[4] Royal Free Hospital,undefined

[5] Hannover Medical School and German Centre for Lung Research (DZL/BREATH),undefined

[6] Medical University of Vienna,undefined

[7] University of Michigan,undefined

[8] Actelion Pharmaceuticals Ltd,undefined

[9] University of California,undefined

[10] San Diego,undefined

[11] Hôpital Bicêtre,undefined

[12] Cedars-Sinai Medical Center,undefined

[13] University of Texas Southwestern Medical Center,undefined

[14] Université Paris-Sud,undefined

[15] INSERM Unité 999,undefined

来源：

Advances in Therapy | 2022年 / 39卷

关键词：

Selexipag; Pulmonary arterial hypertension; PAH; GRIPHON; Open-label extension; Safety; Tolerability; Survival; Combination therapy; Long-term outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：796 / 810

页数：14

共 50 条

[1] Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Galie, Nazzareno
Gaine, Sean
Channick, Richard
Coghlan, J. Gerry
Hoeper, Marius M.
Lang, Irene M.
McLaughlin, Vallerie V.
Lassen, Cheryl
Rubin, Lewis J.
Hsu Schmitz, Shu-Fang
Sitbon, Olivier
Tapson, Victor F.
Chin, Kelly M.
ADVANCES IN THERAPY, 2022, 39 (01) : 796 - 810
[2] Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
Rogério Souza
Marion Delcroix
Nazzareno Galié
Pavel Jansa
Sanjay Mehta
Tomás Pulido
Lewis Rubin
B. K. S. Sastry
Gérald Simonneau
Olivier Sitbon
Adam Torbicki
Neli Boyanova
Liliya Chamitava
Claudia Stein
Richard N. Channick
Advances in Therapy, 2022, 39 : 4374 - 4390
[3] Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
Souza, Rogerio
Delcroix, Marion
Galie, Nazzareno
Jansa, Pavel
Mehta, Sanjay
Pulido, Tomas
Rubin, Lewis
Sastry, B. K. S.
Simonneau, Gerald
Sitbon, Olivier
Torbicki, Adam
Boyanova, Neli
Chamitava, Liliya
Stein, Claudia
Channick, Richard N.
ADVANCES IN THERAPY, 2022, 39 (09) : 4374 - 4390
[4] Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study
Dunbar Ivy
Maurice Beghetti
Ernesto Juaneda-Simian
Ramiya Ravindranath
Mary Ann Lukas
Sandra Machlitt-Northen
Nicola Scott
Jun Narita
Rolf M. F. Berger
European Journal of Pediatrics, 2024, 183 : 2141 - 2153
[5] Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension
Barbera, Joan
Jansa, Pavel
Klings, Elizabeth
Ristic, Arsen
Keogh, Anne
Solum, Derek
Rao, Youlan
Grover, Rob
Saib, Isil
Sood, Namita
ADVANCES IN THERAPY, 2024, 41 (03) : 1062 - 1074
[6] FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion
Berger, Rolf M. F.
Haworth, Sheila G.
Bonnet, Damien
Dulac, Yves
Fraisse, Alain
Galie, Nazzareno
Ivy, D. Dunbar
Jais, Xavier
Miera, Oliver
Rosenzweig, Erika B.
Efficace, Michela
Kusic-Pajic, Andjela
Beghetti, Maurice
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 202 : 52 - 58
[7] Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study
Ivy, Dunbar
Beghetti, Maurice
Juaneda-Simian, Ernesto
Ravindranath, Ramiya
Lukas, Mary Ann
Machlitt-Northen, Sandra
Scott, Nicola
Narita, Jun
Berger, Rolf M. F.
EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (05) : 2123 - 2130
[8] Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension
Joan Barberà
Pavel Jansa
Elizabeth Klings
Arsen Ristić
Anne Keogh
Derek Solum
Youlan Rao
Rob Grover
Isil Saib
Namita Sood
Advances in Therapy, 2024, 41 : 1062 - 1074
[9] Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Hans Klose
Kelly M. Chin
Ralf Ewert
Henning Gall
Joseph Parambil
David Poch
Hans-Jürgen Seyfarth
Lene N. Axelsen
Shu-Fang Hsu Schmitz
Claudia Stein
Ioana R. Preston
Respiratory Research, 22
[10] Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Klose, Hans
Chin, Kelly M.
Ewert, Ralf
Gall, Henning
Parambil, Joseph
Poch, David
Seyfarth, Hans-Jurgen
Axelsen, Lene N.
Schmitz, Shu-Fang Hsu
Stein, Claudia
Preston, Ioana R.
RESPIRATORY RESEARCH, 2021, 22 (01)

← 1 2 3 4 5 →